There are 2789 resources available
718TiP - KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
Presenter: Shahrokh F. Shariat
Session: ePoster Display
801P - Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
Presenter: Emeline Colomba
Session: ePoster Display
720TiP - Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Presenter: Rohit Jain
Session: ePoster Display
727P - Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
Presenter: Alexandra Leary
Session: ePoster Display
728P - A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer
Presenter: Erika Hamilton
Session: ePoster Display
729P - Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC)
Presenter: Judith Kroep
Session: ePoster Display
730P - Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study
Presenter: Huaying Wang
Session: ePoster Display
731P - Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study
Presenter: Robert Morgan
Session: ePoster Display
732P - Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
Presenter: Jueming Chen
Session: ePoster Display